You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Towards a New Generation of Glycoengineered Pneumococcal Bioconjugate Vaccines
SBC: VaxNewMO Topic: NIAIDPROJECT SUMMARY Pneumococcal pneumonia remains the leading cause of bacterial pneumonia in both children under years of age and adults over years of age The standard preventative therapy is the conjugate vaccine Prevnar which consists of an immunogenic carrier protein covalently attached to one of thirteen pneumococcal capsular polysaccharides Although Prevnar has significantly red ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Novel sanitizer against viral infections with long lasting effect
SBC: CAMELLIX, LLC Topic: NIAIDProject Summary Abstract Despite mandatory use of hand sanitizer on cruise ships there are reported cruise ship onboard norovirus outbreaks in exceeded the number of norovirus outbreaks outbreaks onboard cruise ships in One of the problems of currently available alcohol based hand sanitizer is that alcohol evaporates in less than seconds after each application to a surface ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Anti CCL mAb to treat castration resistant prostate cancer
SBC: JYANT Technologies, Inc. Topic: 102Metastatic castration resistant prostate cancer CRPC PCa accounts for of PCa deaths and is associated with skeletal metastases CRPC affects patients differently making this disease difficult for physicians to provide standardized treatments with similar outcomes Docetaxel can prolong the overall survival in patients with metastatic CRPC but current therapies do not provide a cure Doce ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Noninvasive Contrast Enhanced Early Detection of Melanoma Liver Metastasis
SBC: INLIGHTA BIOSCIENCES L.L.C. Topic: 102Abstract The liver is the most common organ for metastasis of various cancersincluding pancreaticovariancolorectalgastric cancers and melanomaUveal melanoma metastasizes inof patients and upon metastasis targets the liver inof these casesThe most common primary malignant liver cancer worldwide is hepatocellular carcinomaHCCThe use of blind liver biopsy as a diagnostic tool for liver cancer has man ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Engineering probiotics to biosynthesize natural substances for microbiome brain research
SBC: HGG Research LLC Topic: RPROJECT SUMMARY To advance microbiome brain studies the general goals of this collaborative proposal are to provide services to research community by engineering probiotics e g E coli Nissle EcN Bifidobacteria longum Lactobacillus plantarum to biosynthesize various naturally occurring chemicals as prebiotic probiotic conjugates which will be marketed as important laboratory agents ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Large Scale Preparation of Natural Glycans
SBC: Natglycan, LLC Topic: 400Project Summary Abstract The two major obstacles to progress in glycomics relative to proteomics and genomics are the lack of simple robust and automated methods for determining glycan structures and for synthesis of glycans The net result of this situation is an overall lack of defined glycans for use in functional studies and for use as standards in structural analysis Significant effort has ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
OC Go Facilitating fidelity and dissemination of evidence based treatment for childhood OCD via an interactive crowd sourced patient provider tool
SBC: VIRTUALLY BETTER INC Topic: 104Project Summary OC Go Facilitating fidelity and dissemination of evidence based treatment for childhood OCD via an interactive crowd sourced patient provider tool The long term objective of this project is to leverage mobile technologies and crowdsourcing to create a new paradigm of evidence based treatment delivery and dissemination as current methods are often insufficient The project seeks ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
ErythroMer Nanoscale Bio Synthetic Red Cell Substitute
SBC: KaloCyte Inc Topic: NHLBIPROJECT SUMMARY There is need for an artificial oxygen O carrier to substitute for banked blood in settings where stored blood is unavailable pre hospital care transport austere environments undeveloped countries or undesirable transfusion risk exceeds benefit To address this need we developed ErythroMer EM a first in class nano cyte blood substitute EM is a deformable ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Enabling point of care molecular diagnostics by developing an adaptive PCR instrument and on demand kit reagents
SBC: BIOVENTURES, INC Topic: 172Because of its high sensitivity polymerase chain reaction PCR is the gold standard for the diagnosis of many infectious diseases but generally only implemented in well equipped laboratories One of the major roadblocks for expanding PCR to point of care markets is the lack of simple robust single tube PCR designs which preserve its laboratory based high sensitivity and specificity In this F ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Small molecule therapy for metastatic prostate cancer
SBC: MetCure Therapeutics LLC Topic: 102Enzalutamide resistance is a major obstacle in the treatment of metastatic castration resistant prostate cancer mCRPC Recently we developed a small molecule lead compound GH and demonstrated its potent activity against bone metastatic prostate cancer cells In this Phase I STTR application we hypothesize that GH is a novel lead compound with nanomolar potency against enzalutamide resist ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health